![Michael Wolff Jensen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Wolff Jensen
Net worth: - $ as of 31/12/2025
Profile
Mr. Michael Wolff Jensen is a Chairman at Vicore Pharma Holding AB, a Chief Executive Officer at Miwo Invest ApS, a Chairman at Xspray Pharma AB, a Chairman at Ascendis Pharma Endocrinology Division A/S, a Chairman, Chief Legal Officer & Senior VP at Ascendis Pharma A/S, a Chairman at Ascendis Pharma Bone Diseases A/S and a Chairman at Ascendis Pharma Growth Disorders AS. He is on the Board of Directors at Visen Pharmaceuticals (Shanghai) Co. Ltd. Mr. Jensen was previously employed as a Chairman by Eurocine Vaccines AB, a Head-France Partnerships by DONG Energy A/S, a Chief Financial Officer & Executive Vice President by LifeCycle Pharma A/S, a Chief Financial Officer & Senior Vice President by Genmab A/S, a President & Chief Executive Officer by EMF Industries A/S, a Chairman by MWJ Invest AB, a Chairman by Paradis A/S, and a Chairman by Vanx ApS. He also served on the board at Azanta A/S. He received his graduate degree from the University of Copenhagen.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ASCENDIS PHARMA A/S -.--% | 31/12/2024 | 0 ( -.--% ) | - $ | 31/12/2025 |
Latest news about Michael Wolff Jensen
| 28/25/28 | Visen Pharmaceuticals Announces Directorate Changes, Effective 27 June 2025 | CI |
| 30/24/30 | Ascendis Pharma A/S : Current Report by Foreign Issuer Form 6 K | PU |
| 03/24/03 | Ascendis Pharma A/S : Form 6-K | PU |
| 08/23/08 | Ascendis Pharma A/S : Form 6-K | PU |
| 06/23/06 | Ascendis Pharma A/S : Form 6-K | PU |
Michael Wolff Jensen active positions
| Companies | Position | Start |
|---|---|---|
| ASCENDIS PHARMA A/S | General Counsel | 01/06/2013 |
Miwo Invest ApS
 Miwo Invest ApS Provides business and other management consulting services | Chief Executive Officer | 28/01/2014 |
Ascendis Pharma Ophthalmology Division A/S | Chairman | - |
Ascendis Pharma, Inc.
 Ascendis Pharma, Inc. Part of Ascendis Pharma A/S, Ascendis Pharma, Inc. is a biopharmaceutical company that focuses on developing new therapies to address unmet medical needs. The company uses their TransCon technology platform to build a fully integrated company that makes a meaningful difference for patients, caregivers, and healthcare professionals. Ascendis Pharma has a pipeline of three endocrinology rare disease product candidates in clinical development and is advancing oncology as a second therapeutic area of focus. The company's unique approach to product innovation focuses on identifying unmet needs where a clinically validated parent drug or pathway is suitable to their TransCone technologies. Ascendis Pharma is committed to making meaningful improvements in patients' lives and making business decisions based on patient needs. The company is based in Palo Alto, CA. | Director/Board Member | - |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Chairman | - |
Ascendis Pharma Growth Disorders AS | Chairman | - |
Ascendis Pharma Bone Diseases A/S | Chairman | - |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Manufactures pharmaceuticals | Director/Board Member | 01/05/2021 |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Manufactures endocrine pharmaceutical products | Chairman | 29/06/2012 |
| ░░░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░ | - |
Former positions of Michael Wolff Jensen
| Companies | Position | End |
|---|---|---|
| ░░░░░ ░░░░░░░░░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Michael Wolff Jensen
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 23 |
|---|---|
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
Eurocine Vaccines AB
 Eurocine Vaccines AB Pharmaceuticals: MajorHealth Technology Develops nasal influenza vaccines | Health Technology |
Genmab A/S
 Genmab A/S Pharmaceuticals: MajorHealth Technology Develops differentiated antibody therapeutics for treatment of cancer | Health Technology |
Ørsted A/S
 Ørsted A/S Electric UtilitiesUtilities Develops, constructs and operates offshore and onshore wind farms, solar farms, energy storage facilities, renewable hydrogen and green fuels facilities and bioenergy plants | Utilities |
Vicore Pharma AB
Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
University of Copenhagen
 University of Copenhagen Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops drug candidates | Health Technology |
Xspray Pharma AB
 Xspray Pharma AB Pharmaceuticals: MajorHealth Technology Develops and produces particulate materials for the pharmaceutical industry | Health Technology |
Paradis A/S | |
EMF Industries A/S | |
Azanta A/S
 Azanta A/S Pharmaceuticals: MajorHealth Technology Provides pharmaceutical drugs within oncology, women's healthcare, and addiction medicine | Health Technology |
Vicore Pharma Holding AB
 Vicore Pharma Holding AB Engages in research and development of drugs for lung diseases | |
MWJ Invest AB | |
Ascendis Pharma, Inc.
Ascendis Pharma, Inc. Part of Ascendis Pharma A/S, Ascendis Pharma, Inc. is a biopharmaceutical company that focuses on developing new therapies to address unmet medical needs. The company uses their TransCon technology platform to build a fully integrated company that makes a meaningful difference for patients, caregivers, and healthcare professionals. Ascendis Pharma has a pipeline of three endocrinology rare disease product candidates in clinical development and is advancing oncology as a second therapeutic area of focus. The company's unique approach to product innovation focuses on identifying unmet needs where a clinically validated parent drug or pathway is suitable to their TransCone technologies. Ascendis Pharma is committed to making meaningful improvements in patients' lives and making business decisions based on patient needs. The company is based in Palo Alto, CA. | |
Miwo Invest ApS
Miwo Invest ApS Provides business and other management consulting services | |
Vanx ApS | |
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S Manufactures endocrine pharmaceutical products | |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. Manufactures pharmaceuticals | |
Ascendis Pharma Bone Diseases A/S | |
Ascendis Pharma Ophthalmology Division A/S | |
Ascendis Pharma Oncology Division A/S | |
Ascendis Pharma Growth Disorders AS | |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Develops, manufactures and commercializes paradigm-shifting endocrine therapies |
- Stock Market
- Insiders
- Michael Wolff Jensen
